Compare Stocks

Genius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. It develops comprehensive entrepreneurial education curriculum with a full suite of tools for student learning and faculty earning. The company also owns entrepreneur resorts in Bali and South Africa, which run entrepreneur retreats and workshops; and Genius Café, an entrepreneur beach club in Bali, as well as Genius Central, an entrepreneur co-working hub in Singapore. In addition, it offers home childcare and investment education services; operates entrepreneur education campus that provides a range of programs from pre-primary through primary school, secondary school, and vocational college; and provides career-focused on-campus and online programs at the master's, bachelor's and associate degree level, as well as certificate and continuing education programs. The company operates in Europe/the Middle East/Africa, the Asia/Pacific, and North America/South America. Genius Group Limited was founded in 2002 and is headquartered in Singapore.

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.